Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 4—April 2012

Dispatch

Human Parvovirus 4 Infection, Cameroon

Myriam Lavoie, Colin P. Sharp, Jacques PépinComments to Author , Christopher Pennington, Yacouba Foupouapouognigni, Oliver G. Pybus, Richard Njouom, and Peter Simmonds
Author affiliations: Université de Sherbrooke, Sherbrooke, Quebec, Canada (M. Lavoie, J. Pépin); University of Edinburgh, Edinburgh, Scotland, UK (C.P. Sharp, C. Pennington, P. Simmonds); Centre Pasteur du Cameroun, Yaoundé, Cameroon (Y. Foupouapouognigni, R. Njouom); University of Oxford, Oxford, UK (O. Pybus)

Main Article

Table 2

Correlates of study participants and human parvovirus 4 infection in multivariate analysis, Cameroon, 2009

Participant characteristic All participants

After exclusions*
Adjusted odds ratio (95% CI) p value Adjusted odds ratio (95% CI) p value
Age group, y
60–64 2.21 (1.13–4.31) 0.02 2.88 (1.16–7.17) 0.02
65–69 1.01 (0.46–2.24) 0.98 1.20 (0.39–3.70) 0.76
70–74 1.16 (0.54–2.46) 0.71 1.51 (0.55–4.16) 0.42
>75 1.00 1.00
Tuberculosis
No 1.00 1.00
Yes, treated with oral drugs only 2.09 (0.58–7.54) 0.26 2.91 (0.63–13.51) 0.17
Yes, treatment included streptomycin 5.21 (0.99–27.37) 0.05 20.96 (1.67–262.99) 0.02
Vaccine scar, left arm
Absent 1.00 1.00
Present 0.37 (0.19–0.71) 0.003 0.32 (0.13–0.78) 0.01
Intravenous treatment for malaria 0.06
No 1.00 1.00
Yes 1.92 (1.13–3.24) 0.015 1.98 (0.97–4.03) 0.06

*After exclusion of 81 participants with borderline negative results and 35 with borderline positive results.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO